|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0010583,
umls-concept:C0015133,
umls-concept:C0030705,
umls-concept:C0032952,
umls-concept:C0033223,
umls-concept:C0039736,
umls-concept:C0040808,
umls-concept:C0393022,
umls-concept:C0677725,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-5-25
|
|
pubmed:abstractText |
Targeting the tumor microenvironment and angiogenesis is a novel lymphoma therapeutic strategy. The authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2655-64
|
|
pubmed:dateRevised |
2011-4-27
|
|
pubmed:meshHeading |
pubmed-meshheading:20235190-Aged,
pubmed-meshheading:20235190-Aged, 80 and over,
pubmed-meshheading:20235190-Antibodies, Monoclonal,
pubmed-meshheading:20235190-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20235190-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20235190-Cyclophosphamide,
pubmed-meshheading:20235190-Etoposide,
pubmed-meshheading:20235190-Female,
pubmed-meshheading:20235190-Humans,
pubmed-meshheading:20235190-Lymphoma, Mantle-Cell,
pubmed-meshheading:20235190-Male,
pubmed-meshheading:20235190-Middle Aged,
pubmed-meshheading:20235190-Neovascularization, Pathologic,
pubmed-meshheading:20235190-Prednisone,
pubmed-meshheading:20235190-Procarbazine,
pubmed-meshheading:20235190-Quality of Life,
pubmed-meshheading:20235190-Recurrence,
pubmed-meshheading:20235190-Thalidomide,
pubmed-meshheading:20235190-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, New York, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
